Budget impact analysis of Haemate-P as long-term prophylaxis and on-demand therapy for von Willebrand disease in Spain.

Objectives: A decision-analytic model was developed to assess the Spanish healthcare system budget impact associated with increased use of Haemate-P in individuals with von Willebrand disease.

Methods: The model considered long-term prophylaxis and on-demand treatment with each of three von Willebrand factor (vWF) replacement products (Haemate-P, Fanhdi, and Wilate). Two budget scenarios were considered: a status quo scenario (no changes in uptake of products/strategy) and an alternative scenario (increased Haemate-P uptake). The model estimated total product costs and other medical costs for each budget scenario annually over 3 years. Total budget impact was estimated by subtracting the costs for the status quo scenario from the costs for the alternative scenario.

Results: The alternative Haemate-P uptake scenario was estimated to save the Spanish healthcare system €5.64 million over 3 years. Cost savings were driven primarily by a reduction in vWF product costs (-€5.62 million) resulting from a reduction in vWF product use (-€4.80 million) and bleed reductions (-€0.82 million). In univariate and multiway deterministic sensitivity analyses, the alternative scenario remained cost-saving.

Conclusion: Haemate-P was found to be a cost-saving strategy, and increased use of Haemate-P over Fanhdi, and Wilate is expected to reduce overall costs to the healthcare system in Spain.